Skip to main content

TOP - February 2015, Vol 8, No 1

From the Editors
By Patrick J. Medina, PharmD, BCOP; Steven Stricker, PharmD, MS, BCOP
From the Editors
TOP - February 2015, Vol 8, No 1
In its eighth year, The Oncology Pharmacist (TOP) will continue to provide oncology pharmacists and their colleagues with the latest research findings and results of large clinical trials, interviews with thought leaders, as well as content for pharmacy students and residents, and articles on practice management. Read More ›
St. Joseph’s/Candler Health System
Cancer Center Profile
TOP - February 2015, Vol 8, No 1
St. Joseph’s/Candler Health System was established through a joint operating agreement between 2 religious institutions—St. Joseph’s, a Catholic hospital, and Candler, a Methodist hospital. It is the only faith-based healthcare system in southeast Georgia. Read More ›
Biosimilars: Ambiguity of FDA Terminology and Benefits of a Multidisciplinary Review Team
By Chase Doyle
Best Practices
TOP - February 2015, Vol 8, No 1
Because of the complexity of biosimilar regulations, a pharmaceutical and therapeutics committee—which includes pharmacists and physicians—is recommended to determine appropriate biosimilar use... Read More ›
Addressing Patient Safety for Oral Chemotherapy
By Chase Doyle
Best Practices
TOP - February 2015, Vol 8, No 1
The expanding availability of oral drugs for the treatment of a number of tumor types has increased their use as chemotherapy. Read More ›
Highlights from ASH and SABCS
Conference Correspondent
TOP - February 2015, Vol 8, No 1
The annual meetings of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS) took place in December 2014, attracting US and international oncologists interested in the latest research on basic science and clinical medicine. These are a selection of highlights from these meetings. Read More ›
Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
By Wayne Kuznar
Immunotherapy
TOP - February 2015, Vol 8, No 1
Two programmed cell death receptor-1 (PD-1) inhibitors—the investigational drug nivo­lumab and the recently approved pem­bro­lizumab (Keytruda)—produced dramatic responses in patients with Hodg­kin lymphoma in phase 1 clinical trials. Read More ›
World Cutaneous Malignancies Congress
TOP - February 2015, Vol 8, No 1
The Third Annual World Cutaneous Malignancies Congress (WCMC) took place in San Francisco, CA, on October 30-31, 2014. Read More ›
Venetoclax Moves Forward in Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
By Phoebe Starr
Hematologic Cancers
TOP - February 2015, Vol 8, No 1
The results of a phase 1b study of the combination of venetoclax plus rituximab (Rituxan) showed encouraging safety and excellent activity in patients with chronic lymphocytic leukemia (CLL). Read More ›
8 Prescriptions to Improve Your Finances
By Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF; Andrew D Schwartz, CPA
Financial/Insurance Information
TOP - February 2015, Vol 8, No 1
Why is financial planning important? The term financial planning can be used to illustrate many things. It can be a comprehensive plan, focusing on several needs or goals simultaneously, or limited to specific areas such as establishing a budget, or saving for a home, a child’s education, or retirement. Read More ›

Page 1 of 2